Myeloma Today: Spring 2024

The spring edition of Myeloma Today, is filled with promising developments in the field of myeloma. Here are some highlights: Two New FDA Approvals: Abecma® and Carvykti® CAR T-cell therapies have been approved for earlier use in the myeloma journey, expanding treatment options and improving patient outcomes. Read about interim analyses from clinical trials of combination therapies with Blenrep® and how they demonstrate positive results in progression-free survival. Learn about the newly granted accelerated approval by the FDA for Elrexfio, a BCMA-directed CD3 T-cell engager, for the treatment of relapsed or refractory myeloma.

Also, this issue spotlights IMF's global campaign, Myeloma ACTION Month, which was a huge success as it reached over 52 million people in 36 countries. Finally, find out how you can get involved in advocating for increased cancer research funding and making a difference in the lives of myeloma patients.


Download a Copy   |    Subscribe to Myeloma Today

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.